{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:02:14Z","timestamp":1795006934247,"version":"4.9.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Global pediatric immunization programs with pneumococcal conjugate vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial disease burden of non-PCV serotypes remains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This phase 3, randomized (1:1), double-blind study evaluated safety and immunogenicity of 20-valent PCV (PCV20) relative to 13-valent PCV (PCV13) in healthy infants. Participants received 2 infant doses and a toddler dose of PCV20 or PCV13, with diphtheria-tetanus-acellular pertussis combination vaccine at all doses and measles, mumps, rubella and varicella vaccines at the toddler dose. Primary pneumococcal immunogenicity objectives were to demonstrate noninferiority (NI) of PCV20 to PCV13 for immunoglobulin G geometric mean concentrations after infant and toddler doses and percentages of participants with predefined serotype-specific immunoglobulin G concentrations after infant doses. Safety endpoints included local reactions, systemic events and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 1204 participants were vaccinated (PCV20, n = 601; PCV13, n = 603). One month after the toddler dose, 19\/20 serotypes met NI for immunoglobulin G geometric mean concentrations; serotype 6B narrowly missed NI [PCV20\/PCV13 geometric mean ratio: 0.57 (2-sided 95% confidence interval: 0.48\u20130.67); NI criterion: lower 2-sided 95% confidence interval &gt;0.5]. Sixteen\/twenty serotypes met NI for \u22651 primary objective after 2 infant doses. PCV20 induced robust opsonophagocytic activity, and boosting responses were observed for all vaccine serotypes, including those missing statistical NI. The safety\/tolerability profile of PCV20 was like that of PCV13.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PCV20 3-dose series in infants was safe and elicited robust immune responses. Based on these results and PCV13 experience, PCV20 3-dose series is expected to be protective for all 20 vaccine serotypes. NCT04546425.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000004300","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:08:55Z","timestamp":1709888935000},"page":"587-595","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":36,"title":["Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers"],"prefix":"10.1097","volume":"43","author":[{"given":"Piotr","family":"Korbal","sequence":"first","affiliation":[{"name":"From the IN-VIVO, Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[{"name":"Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Jackowska","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center of Postgraduate Medical Education, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kline","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Tamimi","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Drozd","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanyu","family":"Lei","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Peng","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Giardina","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Pearl River, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gruber","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Pearl River, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Scott","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Watson","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.","volume":"8","author":"Said","year":"2013","journal-title":"PLoS One"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States.","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016.","volume":"18","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R5-20250614","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2014use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12879-015-1147-x","article-title":"Pneumococcal serotype evolution in Western Europe.","volume":"15","author":"Tin Tin Htar","year":"2015","journal-title":"BMC Infect Dis"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1016\/j.vaccine.2020.08.068","article-title":"Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis.","volume":"38","author":"Chapman","year":"2020","journal-title":"Vaccine"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid2706.204238","article-title":"Twenty-year public health impact of 7- and 13-valent pneumococcal conjugate vaccines in US children.","volume":"27","author":"Wasserman","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15.","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis.","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/21645515.2015.1118593","article-title":"Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement.","volume":"12","author":"Hausdorff","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"Supplement_1","key":"R13-20250614","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1093\/ofid\/ofaa439.486","article-title":"Selected impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD) at eight children\u2019s hospitals in the United States. 2014\u20132019.","volume":"7","author":"Kaplan","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/ciaa917","article-title":"Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation.","volume":"72","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/cid\/ciw067","article-title":"Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine.","volume":"62","author":"Tomczyk","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"60.e9","DOI":"10.1016\/j.cmi.2015.08.027","article-title":"Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA.","volume":"22","author":"Metcalf","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study.","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/cid\/cix310","article-title":"Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006-2014.","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/21645515.2016.1277300","article-title":"Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world.","volume":"13","author":"Cui","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2019.08.048","article-title":"Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.","volume":"37","author":"Thompson","year":"2019","journal-title":"Vaccine"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age.","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination.","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years.","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.1128\/mSphere.00128-18","article-title":"Development and validation of 13-plex Luminex-based assay for measuring human serum antibodies to Streptococcus pneumoniae capsular polysaccharides.","volume":"3","author":"Pavliakova","year":"2018","journal-title":"mSphere"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.1093\/ofid\/ofz360.1201","article-title":"Development, maintenance, and application of opsonophagocytic assays to measure functional antibody responses to support a 20 valent pneumococcal conjugate vaccine.","volume":"6","author":"Scully","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"e00127-18","DOI":"10.1128\/mSphere.00127-18","article-title":"Evaluation of a validated Luminex-based multiplex immunoassay for measuring immunoglobulin G antibodies in serum to pneumococcal capsular polysaccharides.","volume":"3","author":"Tan","year":"2018","journal-title":"mSphere"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/cid\/ciab645","article-title":"Dynamics of invasive pneumococcal disease in Israel in children and adults in the 13-valent pneumococcal conjugate vaccine (PCV13) era: a nationwide prospective surveillance.","volume":"74","author":"Ben-Shimol","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"13332","DOI":"10.1038\/s41598-022-17600-6","article-title":"Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018.","volume":"12","author":"Cleary","year":"2022","journal-title":"Sci Rep"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"2200765","DOI":"10.2807\/1560-7917.ES.2023.28.25.2200765","article-title":"Dynamics of invasive pneumococcal disease in infants < 2 years old following PCV7\/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019.","volume":"28","author":"Ben-Shimol","year":"2023","journal-title":"Euro Surveill"},{"key":"R43-20250614","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.vaccine.2023.04.017","article-title":"Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1\u2009+\u20091) compared to two primary doses and a booster (2\u2009+\u20091) in UK infants.","volume":"41","author":"Goldblatt","year":"2023","journal-title":"Vaccine"},{"key":"R44-20250614","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"R46-20250614","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1016\/j.vaccine.2009.03.087","article-title":"Challenges in the evaluation and licensing of new pneumococcal vaccines, 7\u20138 July 2008, Ottawa, Canada.","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"},{"key":"R47-20250614","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1016\/j.vaccine.2009.06.098","article-title":"Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.","volume":"27","author":"Russell","year":"2009","journal-title":"Vaccine"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S1473-3099(20)30775-1","article-title":"Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial.","volume":"21","author":"Licciardi","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1016\/j.vaccine.2013.08.009","article-title":"Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.","volume":"31","author":"Rodgers","year":"2013","journal-title":"Vaccine"},{"key":"R50-20250614","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.vaccine.2022.12.054","article-title":"A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).","volume":"41","author":"Lupinacci","year":"2023","journal-title":"Vaccine"},{"key":"R51-20250614","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1016\/j.vaccine.2023.04.036","article-title":"A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).","volume":"41","author":"Martinon-Torres","year":"2023","journal-title":"Vaccine"},{"key":"R52-20250614","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1093\/cid\/ciac475","article-title":"Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination.","volume":"76","author":"Grant","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R53-20250614","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/INF.0000000000001845","article-title":"Characteristics of children with invasive pneumococcal disease after the introduction of the 13-valent pneumococcal conjugate vaccine in England and Wales, 2010-2016.","volume":"37","author":"Makwana","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R54-20250614","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014-2018.","volume":"71","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R55-20250614","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1473-3099(20)30165-1","article-title":"Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.","volume":"21","author":"Ouldali","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R56-20250614","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/17843286.2022.2039865","article-title":"The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.","volume":"78","author":"Janssens","year":"2023","journal-title":"Acta Clin Belg"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T20:02:18Z","timestamp":1749931338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004300","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}